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Cyclosporin A inhibits prostaglandin E2 formation by rat mesangial
cells in culture. A reversible reduction in glomerular filtration rate
(GFR) is a frequent side effect in patients treated with the immunosup-
pressant cyclosporin A (C5A). The pathophysiology of acute CsA
nephrotoxicity, however, is unclear. Since eicosanoids are local medi-
ators of glomerular hemodynamics, they might be involved in CsA
induced changes in GFR. We therefore studied the effect of CsA on
prostaglandin E2 (POE2) production by rat mesangial cells in culture.
POE2 production by mesangial cells following stimulation with angio-
tensin II (All) (10—6 54) or the Ca2-ionophore A23187 (I g/ml) was
significantly inhibited when cells were grown for 24 hours in media
which contained CsA (800 to 3200 ng/ml). CsA did not affect viability of
mesangial cells as determined by 51Cr release or by cell proliferation
measured by 3H-thymidine incorporation. CsA (3200 ng/ml) did not
inhibit PGE2 formation by rat MC microsomes incubated with arachi-
donic acid. However, CsA, in a dose dependent manner, inhibited
A23187 and angiotensin IL induced release of 3H-labelled arachidonic
acid from rat mesangial cells. These data demonstrate that CsA reduces
PGE2 formation by rat mesangial cells in culture, probably by inhibiting
the release of substrate arachidonic acid from cell membranes rather
than by inhibition of cyclooxygenase. This effect may contribute to the
reduction in GFR which accompanies CsA therapy.
A reduction in glomerular filtration rate (GFR) is one major
side effect of cyclosporin A (CsA) treatment, both in patients
receiving immunosuppression for organ transplantation [1—4]
and in patients being treated for autoimmune diseases [5—7].
This early nephrotoxic effect of CsA is often rapidly reversible
after withdrawal of the immunosuppressant [7—9] and is unac-
companied by significant renal structural damage suggesting a
functional hemodynamic process [4]. Administration of CsA to
rats in doses similar to those used in humans results in a marked
increase in renal vascular resistance with a consequent reduc-
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tion in renal perfusion and GFR of similar magnitude to that
observed during acute CsA nephrotoxicity in man [10, 11]. The
impairment of whole kidney GFR in rats following CsA is due to
a decrease in glomerular plasma flow and ultrafiltration coeffi-
cient K [12, 131. Recent data from renal transplant recipients
demonstrate that the urinary excretion of vasodilatory PGE2 in
patients treated with CsA is considerably lower than that in
patients treated with conventional immunosuppression [14, 15].
In addition, in animal studies, CsA inhibits renal PGE2 [16] and
vascular PGI2 [17] formation, transiently reduces urinary PGE2
excretion [18], and increases excretion of cyclooxygenase me-
tabolite thromboxane B2 (CT x B2) [19].
Arachidonic acid metabolites are important in the control of
glomerular hemodynamics [20], and inhibition of glomerular
production of vasodilatory prostanoids could contribute to the
reduced GFR observed during CsA treatment. Since mesangial
cell production of PGE2 appears to be important in counteract-
ing vasoconstrictive stimuli in the glomerulus [20, 21], the
present investigation was designed to determine if CsA altered
PGE2 production by rat mesangial cells in culture. Our data
demonstrate that CsA, in a dose dependent manner, reduces
PGE2 formation by mesangial cells independently of any cyto-
toxic effect. This reduction apparently results from inhibition of
substrate arachidonic acid release from cell membranes rather
than from inhibition of cyclooxygenase enzyme activity.
Methods
Reagents
Fatty acid-free bovine serum albumin (BSA), indomethacin,
and arachidonic acid were obtained from Sigma Chemical
Company, St. Louis, Missouri, USA. The Ca-ionophore
A23 187 was purchased from Cal Biochemicals (Behring Diag-
nostics, San Diego, California, USA). Prostaglandin E2 (PGE2)
standard was obtained from Upjohn Diagnostics (Kalamazoo,
Michigan, USA). 3H-PGE2, 3H-arachidonic acid and 51Cr were
obtained from New England Nuclear (Boston, Massachusetts,
USA). Antisera for PGE2 assays were from the Institut Pasteur
(Paris, France) and have been described elsewhere [22]. Silica
gel thin layer chromatography (TLC) plates were obtained from
Merck (Darmstardt, FRG). Organic solvents were from Baker
Chemicals (Phillipsberg, New Jersey, USA). Reagents for tis-
sue culture of mesangial cells were obtained from Irvine Scien-
tific (Santa Ana, California, USA) and Gibco Laboratories
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(Santa Clara, California, USA). Cyclosporin A was from Dr. B.
Ryffel, Sandoz AG, Base!, Switzerland.
Rat mesangial cell cultures
Mesangial cell cultures were established from glomeruli iso-
lated from the kidneys of male Sprague-Dawley rats as previ-
ously described [23]. Collagenase treated glomeruli were plated
on culture dishes in RPMI 1640 media containing 15% heat-
inactivated fetal calf serum, penicillin (100 U/mi), streptomycin
(100 sg/ml), amphotericin (0.25 pg/mI), and insulin (0.66 U/mi).
Cells in culture displayed the typical spindle or stellate mor-
phology of mesangial cells [23]. Immunofluorescent staining of
the cells was positive with antibodies to myosin, smooth muscle
cell actin, collagens types III and IV and factor VIII (from Dr.
Alan Gown, Department of Pathology, University of Washing-
ton, Seattle, Washington, USA). Cells with the morphologic
aad immunochemical characteristics of epithelial cells were not
detected. Macrophage contamination was excluded by the
absence of immunofluorescent staining with antibody to rat
common leukocyte antigen (Pel-Freeze Biological, Rogers,
Arkansas, USA), negative staining for nonspecific esterase and
the inability of cells to ingest latex particles [24]. Mesangial cell
cultures were maintained at 37°C in 5% CO2 in air and passaged
7 to 10 days after initial plating using trypsin-EDTA (Gibco).
Cells were studied in monolayers after first passage.
Experimental design
In order to assess whether mesangial cell PGE2 formation
was affected by CsA, mesangial cells were incubated for 24
hours with increasing concentrations of CsA, and PGE2 was
determined in the supernatants. No attempts to study effects of
CsA on mesangial cell TxB2 production were made because
TxB2 production by mesangial cells was very low or undetect-
able under both basal and stimulated conditions. Experiments
were performed in the presence and absence of stimulators of
mesangial cell POE2 production (angiotensin II, Ca2-iono-
phore A23 187). Effects of CsA on cell viability were assessed
by 51Cr release, and effects on cell proliferation were deter-
mined by measuring uptake of 5H-thymidine. In order to
determine the possible site of action of CsA, the effect of the
drug on the release of 3H-labelled arachidonic acid from mesan-
gial cell membranes, and on the conversion of arachidonic acid
to PGE2 by cyclooxygenase in mesangial cell microsomes was
tested.
CsA treatment of mesangial cells
To determine the effect of CsA on basal PGE2 formation,
mesangial cells growing in 24-well culture plates (Becton-
Dickenson Company, Oxnard, California, USA) were washed
twice with Hank's balanced salt solution (HBSS). Cells were
then incubated for 24 hours at 37°C in 0.5 ml RPMI media with
0.5% fetal calf serum (FCS) containing increasing concentra-
tions of CsA (200, 800, 1600 and 3200 ng/ml dissolved in 1%
DMSO). Control cells were incubated with media and DMSO
alone. In all studies mean values from six identical wells were
used as a single data point. After 24 hours, supernatants of
CsA-treated and control cells were collected on indomethacin
(2 x l0 M final concentration) and frozen at —70°C until
assayed for POE2. To assess the effect of CsA on stimulated
POE2 production, mesangial cells grown for 24 hours in the
presence of CsA (200, 800 and 1600 and 3200 ng/ml) were
washed twice with HBSS and then exposed to either angioten-
sin II (10_6 M), or Cationophore (1 .tg/ml), in the presence of
CsA (200, 800, 1600 or 3200 ng/ml) in a final volume of 0.5 ml
per well for 30 minutes. Control cells were grown in the absence
of CsA for 24 hours and then exposed to similar concentrations
of angiotensin II and Cationophore in the absence of CsA.
Supernatants were collected as described above. The cells were
then dissolved in 0.2 ml of 1 N sodium hydroxide and assayed
for protein by the method of Lowry et al [25].
51Cr release assay
To assess the effects of CsA on mesangial cell viability, cells
were labelled with 51Cr by incubation overnight with 3 sCi/ml
of sodium 5tCr-chromate in RPMI media containing 5% FCS.
Cells were then washed with HBSS and incubated for 24 hours
with media alone containing 1% DMSO, or increasing concen-
trations of CsA (800, 1600, 3200 ng/ml) dissolved in 1% DMSO.
Counts in the supernatants and total counts remaining in the
cells following lysis in 1% triton x 100 were determined in a
gamma counter (Packard Instrument Company, Downers
Grove, Illinois, USA). Specific release of 51Cr was calculated
from the equation: % specific release = [cpm test — cpm
control]/[total cpm — cpm control] x 100.
3H-thymidine incorporation
To assess the effect of CsA on mesangial cell viability as
determined by effect on basal cell proliferation, mesangial cells
were grown in 96 well plates under conditions as described
above in RPMI 1640 with 15% FCS. Cells were growth arrested
by preincubating for 48 hours in serum free medium. Then the
cells were incubated for 20 hours in cell culture medium + 75%
FCS in the presence of CsA (800, 1600, 3200 ng/ml). After 20
hours the medium was removed and replaced by the same
medium which contained 5H-thymidine (1 pCi/mI). After an
additional four hours, cells were harvested and counted for
3H-activity which was expressed in cpm/well.
Cyclosporin A and arachidonic acid metabolism by mesangial
cell microsomes
To investigate the possibility that the CsA effect on mesangial
cell PGE2 production might be related to an effect on cyclooxy-
genase, mesangial cells were grown in tissue culture flasks in
RPMI 1640 + 15% fetal calf serum until confluent. The media
was removed and cells were washed twice with PBS (pH 7.4)
containing 0.1 mrvi EDTA, 1 ig/ml pepstatin and 0.2 mrsi PMSF
to inhibit proteases.
Cells were then scraped off the tissue culture flasks with a
rubber policeman into PBS containing protease inhibitors.
Pooled mesangial cells were centrifuged at 800 x g for 10
minutes at 4°C, and all subsequent procedures were performed
at 4°C. The pellet was re-dissolved with an 0.1 M potassium
phosphate buffer containing 1% BSA and protease inhibitors
and homogenized with a tissue grinder (Wheaton Scientific,
MilIville, New Jersey, USA). Microsomes were prepared ac-
cording to the method of Sheng et al [26]. The homogenate was
centrifuged for 30 minutes at 8000 x g. The resultant superna-
tant was centrifuged for one hour at 100,000 X g. The pellet was
frozen at —70°C in phosphate buffer with protease inhibitors
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Table 1. Effect of CsA on basal and stimulated POE2 production by rat mesangial cells (pgIlO tg protein/30 mm)
CsA concentration ng/ml
































Abbreviation is: ND, not determined.
aP < 0.001 vs. basalb P < 0.05 vs. angiotensin II without CsA
P < 0.01 vs. A23187 without CsA
and without BSA. The storage time did not exceed one month.
The pellet was re-constituted in 0.1 M phosphate buffer, soni-
cated and the protein content adjusted to 50 to 100 tg/l00 d.
Samples were incubated at 37°C in a water bath, and the
reaction started by adding arachidonic acid, 75 LM final con-
centration. CsA (3200 ng/ml) or indomethacin (l0— M) was
added to the microsomes prior to adding substrate. The reaction
was stopped by the addition of 0.7 ml of iced radioimmunoassay
buffer. The samples were immediately frozen at —70°C. In
additional experiments, mesangial cell microsomes with en-
zyme activity destroyed by boiling for 30 minutes in phosphate
buffer were incubated with 75 kM arachidonic acid under the
same conditions described above. Samples were then assayed
for PGE2 activity as described below.
Cyclosporin A effect on release of 3H-labelled arachidonic
acid from mesangial cells
To further evaluate the possibility that the CsA effect on
mesangial cell PGE2 production might be related to release of
arachidonic acid substrate from mesangial cell membranes,
mesangial cells were grown as described above. Labeling of the
cell membrane arachidonic acid was performed according to
Schlorndorff, Perez and Satriano [27]. Mesangial cells were
washed twice with HBSS and incubated with 4 Ci 3H-arachi-
donic acid/well in 0.5 ml for three hours at 37°C in culture
medium containing 5 mg/mI fatty acid-free BSA. After three
hours supernatants were removed and the cells were washed
twice with fatty acid-free BSA medium. Cells were incubated
for 24 hours in 0.5 ml of culture medium plus 0.5% FCS
containing cyclosporin A (1600, 3200, 4800, 6400, ng!ml). Con-
trol cells were incubated without CsA. Cells were then exposed
to Ca-ionophore A23187 (1 g/ml) or angiotensin 11(10—6 M) in
0.5 ml HBSS for 30 minutes. When angiotensin II was added,
mesangial cells were incubated with 3200 ng/ml of CsA. Super-
natants were collected on indomethacin (2 x l0— M final
concentration) and frozen at —70°C until extraction and sepa-
ration on TLC. A fraction of the supernatant was counted for
3H-activity to account for the total amount of label released.
Cells were lysed in 0.2 ml NaOH and a fraction was counted for
3H-activity to determine the total amount of 3H-arachidonic
acid incorporated in the cells. Cell protein was determined
according to the method of Lowry et al [25].
Measurement of PGE2 by radioimmunoassay
Prostaglandin E2 released from mesangial cells in culture was
measured by direct radioimmunoassay of the supernatant with-
out prior extraction and separation of medium. When arachi-
donic acid was added to mesangial cell microsomes, samples
without microsomes were also assayed for PGE2 to account for
possible cross reactivity of the antiserum with arachidonic acid.
The concentrations of arachidonic acid used in these experi-
ments (75 tM) did not cross react with our PGE2 antiserum. The
cross reactivity of the antiserum and the assay procedure have
been previously described [22].
In experiments where 3H-labelled arachidonic acid was used,
cell supernatants or incubation media were acidified to pH 3.5
with 1 N HCL and subsequently extracted three times with 10 to
15 volumes of ethyl acetate. Extracts were dried under N2 and
reconstituted with methanol. Together with PGE2 and arachi-
donic acid standards, the 3H-arachidonic acid and the arachi-
donic acid products were separated on thin layer chromatogra-
phy as described previously [22]. Standards were visualized by
iodine vapor, and the zones corresponding to PGE2 and arachi-
donic acid were scraped off the plates, extracted in methanol
and counted in a liquid scintillation counter.
Statistical analysis
All values are expressed as means Comparisons be-
tween means of groups was done using Student's t-test with
correction for multiple comparisons when applicable [28]. A P
value of <0.05 was considered significant
Results
Effect of CsA on basal and stimulated production of PGE2 by
mesangial cells
The values for PGE2 production by mesangial cells incubated
with varying concentrations of CsA under basal and stimulated
conditions are given in Table 1. When control mesangial cells
grown for 24 hours without CsA were exposed to HBSS for 30
minutes they released 1189 107 pg PGE2/l0 p.g cellular
protein (Table 1). Mesangial cells grown for 24 hours under the
same conditions but in the presence of 1600 ng!ml CsA released
only 578 98 pg/b g/30 mm (P < 0.001). CsA at 200 ng and
800 ng/ml did not significantly influence basal POE2 production
by rat mesangial cells in culture.
In control mesangial cells grown in culture media and DMSO
without CsA, angiotensin II and the Ca-ionophore A23 187
stimulated mesangial cell PGE2 formation to 1966 221 pgll0
g/30 mm (P < 0.001 vs. unstimulated controls) and 11095
1190 pg/lO pg/30 mm, respectively (P < 0.001 vs. unstimulated
control; Table 1). Incubation with CsA for 24 hours at concen-
trations from 800 to 3200 ng/ml completely abolished the
stimulatory effect of angiotensin II on POE2 formation, and
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Baseline 3j incorporation 64,943 5000 70,975 7541 82,655 11433 73,186 6164 61,797 8119 71,094 10385
cpm
5H arachidonic acid release ND 10,904 1974 9,814 2081 4,360 ga 3,720 82T 2,360 388U
cpmIiO jig/protein/30 mm
3H PGE2 release ND 3,036 458 2,711 423 1,074 14& 1,029 174k 595 128a
(cpm/10 jig/protein/30 mm)
Abbreviation is ND, not determined.
a < 0.001 vs. 0 GSA
Table 3. Effect of CsA on angiotensin Il-stimulated mesangial cell
release of 3H-labelled arachidonic acid products
Angiotensin II
10-6 M + CsA
Control 10-6 M 3200 ng/ml
N=6 N=3 N=3
Baseline 3H- 68818 4567 67552 5163 72515 1777
incorporation
cpm/10 jig protein
3H-AA release 3162 617 4545 418a 3164 2786
cpm/I0 jig/protein!
30 mm
3H-POE2 release 687 63 993 l04 672 996
cpm/10 jig protein!
30 mm
a P c 0.05 vs. control
6 p < 0.05 vs. All
reduced significantly the increase in POE2 production after
exposure of the cells to A23 187 (Table 1).
Effect of GsA on cyclooxygenase activity in rat mesangial
cell microsomes
When mesangial cell microsomes were incubated without
arachidonic acid under the conditions described above they
generated 2080 451 pg/80 jig protein/S mm of POE2. In the
presence of 75 M arachidonic acid, POE2 formation increased to
6080 1040 pg/80 jig protein/S mm (P C 0.05). This effect was
significantly inhibited by indomethacin (3045 472 pg/so jig/S
mm). However, stimulation induced by arachidonic acid was
unaffected by CsA (3200 ng/ml; 5637 632 pg/80 jig/S mm).
When microsomes were boiled prior to incubation to inactivate
cyelooxygenase, POE2 formation averaged 217 43 pg/80 jig/S
mm. POE2 was undetectable by our RIA system when arachi-
donic acid in the concentrations studied here was incubated
without microsomes in the presence of indomethacin or CsA
alone.
Effect of cyclosporin A on A23187 and angiotensin II
stimulated release of 3H-labelled arachidonic acid products
To study the effect of CsA on the release of 5H-labelled
arachidonic acid and POE2, mesangial cells were labelled with
3H-arachidonie acid as outlined under Methods. The amount of
H incorporated into mesangial cells prior to exposure to
A23187 alone or A23187 + CsA was not different between the
groups studied (Table 2). Mesangial cells in media alone re-
Table 4. Effect of CsA on mesangial cell viability assessed
release and 3H tbymidine uptake
by 5tCr
CsA concentration jig/rn!
0 800 1600 3200
0 5.5±6.7 3.8±4.4 3.4±3.5% Specific 51Cr release
mean so, N = 16
3H-thymidine uptake 396 15 438 21 423 40 408 28
cpm/well, N = 12
leased detectable amounts of 5H-AA and 5H-POE2 (Table 2).
A23 187 induced a significant release of 3H-AA (10904 1974
cpm/l0 jig/30 mm) and 3H-PGE2 (3036 458 cpm/lO jig/30 mm;
Table 2). CsA in concentrations from 3200 to 6400 ng/ml
significantly inhibited the amounts of 3H labelled material which
comigrated with AA and POE2 standards on thin layer chroma-
tography (Table 2).
Effect of CiA on angiotensin II stimulated release of 3j
labelled arachidonic acid products
Table 3 summarizes the effect of CsA (3200 ng/ml) on the
release of 3H-labelled material from rat mesangial cells which
were treated with angiotensin II. There was no difference in the
incorporation of 3H-labelled AA. Angiotensin II significantly
stimulated the release of 3H-labelled material, which comi-
grated with AA and POE2 standards on TLC. This stimulatory
effect of angiotensin II was significantly inhibited when CsA
(3200 ng/ml) was present in the incubation media.
Effect of CsA on mesangial cell viability
Mesangial cell viability as assessed by morphologic criteria,
specific 51Cr release and baseline proliferation of cells in culture
measured by 3H-thymidine uptake was not affected by GsA in
doses ranging from 800 to 3200 ng/ml (Table 4).
Discussion
The incubation of rat mesangial cells for 24 hours in tissue
culture media that contained CsA at a concentration of 1600 ng/
ml resulted in a 50% decrease of POE2 formation compared to
mesangial cells which were grown in media without the immu-
nosuppressant.
When untreated mesangial cells were exposed to the vaso-
constrictor peptide angiotensin II and the Ca2-ionophore A
23187, POE2 synthesis was significantly stimulated, a phenom-
enon already noted by others [20}. Angiotensin II increased
POE2 formation by about 50%, whereas A 23187 enhanced
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mesangial cell prostaglandin production by almost 10-fold.
CsA, in concentrations above 800 ng/ml, completely blocked
the stimulatory effect of angiotensin II on mesangial cell PGE2
formation and reduced, in a dose dependent manner, mesangial
cell prostanoid formation after exposure to the Ca2-ionophore.
These data demonstrate that CsA can reduce baseline produc-
tion of PGE2 by rat mesangial cells in culture both by blocking
the effect of specific, probably receptor mediated, effects of
angiotensin II [20, 29, 30] and by partially reducing the nonspe-
cific stimulation produced by calcium ionophore [27]. When
cells were studied under basal conditions a significant effect was
only found at CsA concentrations of 1600 ng/ml and above.
However, the inhibitory effect of CsA on PGE2 formation under
stimulated conditions was significant at concentrations of 800
ng/ml. The concentrations of CsA employed in these studies
exceed conventional therapeutic levels attained in serum in
vivo in man. However, they probably do not exceed tissue
levels which are considerably higher in most animal species and
man with tissue to blood ratios from 2 to 50 [31]. In addition,
there may be a difference in the threshold for nephrotoxicity
between man and rat. In the rat, acute or chronic forms of
nephrotoxicity appear when oral doses above 20 mg/kg are
administered [32]. These doses usually lead after several days
to whole blood levels which average between 3000 and 4000 ng/
ml. These serum levels are higher than the concentrations
which were found to inhibit PGE2 formation. Therefore, we
believe that the concentrations used in our study do not exceed
levels which may cause nephrotoxicity in vivo.
The difference in mesangial cell sensitivity to CsA between
unstimulated and stimulated cells suggests that the inhibitory
effect is more pronounced in situations where mesangial cell
prostaglandin production is stimulated. In fact, in in vivo
experiments we have observed that the inhibitory effect of CsA
on PGE2 production by the intact kidney is more pronounced
when PGE2 formation is stimulated either by arachidonic acid
or by furosemide [16]. Similar results have been reported in a
model of acute renal failure [33].
CsA in the concentrations used in these experiments exerts
its effect on PGE2 production by mesangial cells without any
apparent influence on cell viability as determined by 51Cr
release or on cell proliferation as determined by 3H-thymidine
uptake. The present data in vitro confirm our earlier observa-
tions of a CsA effect on renal PGE2 formation in a combined in
vivo/in vitro approach, which demonstrated reduced glomerular
and medullary PGE2 biosynthesis following CsA treatment [16].
The inhibitory effect of CsA on PGE2 formation by mesangial
cells following angiotensin II exposure may provide a mecha-
nism whereby CsA reduces GFR in vivo through an effect on
prostaglandin mediated regulation of intraglomerular hemody-
namics. Since PGE2 decreases glomerular contraction due to
angiotensin II [34], CsA induced inhibition of glomerular PGE2
formation may lead to reduced filtration surface area and thus
reduced GFR. In addition to an effect on the reduction of PGE2
CsA may enhance contractility of mesangial cells due to a
prolonged increase in cytosolic calcium, which has recently
been demonstrated [35]. This interpretation of cyclosporine's
effect on GFR is supported by a recent observation of Barros et
al [13]. They found in micropuncture studies that treatment of
rats with indomethacin did not affect CsA induced reduction in
GFR. Vasodilatory prostaglandins only mediate glomerular
hemodynamics if production is stimulated due to stress to the
kidney [36]. If glomerular PG formation is inhibited, as has been
demonstrated with CsA [16], the additional treatment with a
cyclooxygenase inhibitor should not further alter renal hemo-
dynamics, at least that portion of GFR regulation mediated by
PG.
In order to clarify the possible mechanism of action of CsA
on mesangial cell PGE2 formation, we studied the effect of the
immunosuppressant on arachidonic acid induced PGE2 forma-
tion by mesangial cell microsomal cyclooxygenase. When
mesangial cell microsomes were incubated with arachidonic
acid for five minutes, radioimmunoassayable PGE2 formation
was increased by threefold over baseline production. The
cyclooxygenase inhibitor indomethacin significantly reduced
the stimulatory effect of arachidonic acid on PGE2 biosynthesis.
However, CsA at a concentration of 3200 ng/ml, which signif-
icantly reduces angiotensin II and A 23187 induced PGE2
formation, did not affect the conversion of arachidonic acid to
the prostanoid. These findings suggest that the inhibitory influ-
ence of CsA is probably not due to an effect on cyclooxygenase
activity.
An alternative mechanism for the CsA effect observed would
be that CsA directly inhibits the release of substrate arachidonic
acid from mesangial cell membranes thereby reducing PGE2
production. To further assess this possibility, the influence of
the drug was tested on the release of 3H-labelled arachidonic
acid from labelled rnesangial cells following A23 187 or angio-
tensin II stimulation. A23l87 and angiotensin II both induced a
significant increase of 3H-labelled material which comigrated
with AA and PGE2 standards. This increase was significantly
inhibited by CsA in concentrations above 1600 ng/ml. We
presume that apparent discrepancy between the concentrations
of CsA required to inhibit PGE2 formation (1600 ng/ml) and that
required to inhibit 3H-arachidonic acid release (3200 ng/ml)
probably reflects the fact that techniques for measuring tritiated
arachidonic acid are less sensitive than the radioimmunoassay
for PGE2. These observations suggest that CsA might interfere
with the release of arachidonic acid from mesangial cells and
that the reduction of substrate availability might be a responsi-
ble mechanism for inhibited PGE2 formation. Since A23 187 and
angiotensin II mediated release of arachidonic acid is thought to
be primarily mediated by phospholipase A2 in mesangial cells
[27], CsA could exert its effect on phospholipase A2 activity. In
fact, recent data demonstrate that CsA, in a dose dependent
manner, inhibits phospholipase A2 activity [37]. In addition,
recent data suggest that CsA binds to calmodulin and appears to
inactivate calcium-dependent cellular activities [38]. Since ac-
tivation of phospholipase A2 due to Ca2 is also mediated
through calmodulin [39, 401, the intracellular mechanism of CsA
could be affected by inhibition of calmodulin activity. Another
mechanism by which CsA might affect arachidonic acid metab-
olism is operative in lymphocytes stimulated by the lectin
concanavalin A. Szamel, Berger and Resch [41] found that CsA
in a dose dependent manner reduced arachidonic acid incorpo-
ration into cell membrane phospholipids due to inhibition of
lysophosphatide acyltransferase. Thus reduced arachidonic
acid incorporation might also be a responsible mechanism for
reduced cyclooxygenase substrate availability.
CsA has not only been shown to reduce renal prostaglandin
formation [16—18], there are also data which demonstrate an
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increase in urinary prostaglandin and TxB2 excretion and
elevated prostaglandin levels in the renal venous effluent of an
isolated perfused kidney model following CsA [42], These data
do not exclude the possibility that glomerular prostaglandins
are inhibited, since Schlondorif et al [431 demonstrated recently
in micropuncture studies that urinary prostaglandins do not
reflect glomerular prostaglandin production in vivo, but rather
represent medullary prostaglandin synthesis.
However, elevated TxA2 might mediate the reduction in GFR
due to contraction of mesangial cells [44]. If increased TxA2
mediates CsA toxicity, however, it would have to be of extra
glomerular origin, since we [33] and others [45]have shown that
CsA reduces TxB2 formation in isolated glomeruli and mesan-
gial cells in culture.
In summary, CsA reduces basal, and stimulated, PGE2
production by rat mesangial cells in culture. Our data suggest
that the responsible mechanism of the CsA effect is an inhibi-
tion of arachidonic acid release from mesangial stores rather
than inhibition of cyclooxygenase activity. The inhibitory effect
of CsA on POE2 formation by mesangial cells might have an
effect on regulation of intraglomerular hemodynamics and thus
explain in part the nephrotoxicity of the immunosuppressant.
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